US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

LONZA GROUP AG-UNSPON ADR

us-stock
To Invest in {{usstockname}}
us-stock
$null null(null%) null at 04 Dec 2025 04:38 PM Diagnostics & Research
Lowest Today 0.00
Highest Today 0.00
Today’s Open 0.00
Prev. Close 0.00
52 Week High 73.85
52 Week Low 55.90
Day’s Range: Low null High null
52-Week Range: Low 55.90 High 73.85
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Fundamentals

Market Cap 48766.46 M

PB Ratio 4.4885

PE Ratio 53.1385

Enterprise Value 53085.76 M

Total Assets 19733.00 M

Volume null

Company Financials

Annual Revenue FY24:6574000000 6574.0M, FY23:6717000000 6717.0M, FY22:6223000000 6223.0M, FY21:5409000000 5409.0M, FY20:4508000000 4508.0M

Annual Profit FY24:2160000000 2160.0M, FY23:1816000000 1816.0M, FY22:2438000000 2438.0M, FY21:2110000000 2110.0M, FY20:1848000000 1848.0M

Annual Net worth FY24:636000000 636.0M, FY23:654000000 654.0M, FY22:1215000000 1215.0M, FY21:2944000000 2944.0M, FY20:869000000 869.0M

Quarterly Revenue Q2/2025:3576000000 3576.0M, Q2/2024:3057000000 3057.0M, Q4/2023:3639000000 3639.0M, Q2/2023:3078000000 3078.0M, Q2/2022:null 0.0M

Quarterly Profit Q2/2025:1292000000 1292.0M, Q2/2024:1116000000 1116.0M, Q4/2023:840000000 840.0M, Q2/2023:1108000000 1108.0M, Q2/2022:null 0.0M

Quarterly Net worth Q2/2025:426000000 426.0M, Q2/2024:329000000 329.0M, Q4/2023:244000000 244.0M, Q2/2023:410000000 410.0M, Q2/2022:null 0.0M

Fund house & investment objective

Company Information Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. Its Small Molecules segment provides integrated development and manufacturing services for small molecule drug substances and their intermediates. This segment also supports customers across aspects of design, development, and manufacturing, such as particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. Its Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Organisation Diagnostics & Research

Employees 19299

Industry Diagnostics & Research

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right